Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M. Ellis PA, et al. Int J Cancer. 1997 Aug 7;72(4):608-13. doi: 10.1002/(sici)1097-0215(19970807)72:4<608::aid-ijc10>3.0.co;2-7. Int J Cancer. 1997. PMID: 9259399 Clinical Trial.
The primary use of endocrine therapies.
Howell A, Anderson E, Blamey R, Clarke RB, Dixon JM, Dowsett M, Johnston SR, Miller WR, Nicholson R, Robertson JF. Howell A, et al. Recent Results Cancer Res. 1998;152:227-44. doi: 10.1007/978-3-642-45769-2_22. Recent Results Cancer Res. 1998. PMID: 9928561 Review.
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M. Robertson JF, et al. Among authors: nicholson ri. Cancer Res. 2001 Sep 15;61(18):6739-46. Cancer Res. 2001. PMID: 11559545 Clinical Trial.
Endocrine therapy--current benefits and limitations.
Nicholson RI, Johnston SR. Nicholson RI, et al. Breast Cancer Res Treat. 2005;93 Suppl 1:S3-10. doi: 10.1007/s10549-005-9036-4. Breast Cancer Res Treat. 2005. PMID: 16247594 Review.
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.
Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, Nicholson RI. Gee JM, et al. Among authors: nicholson ri. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S1-7. doi: 10.1677/erc.1.01054. Endocr Relat Cancer. 2005. PMID: 16113086 Review.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. Kuter I, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7. Breast Cancer Res Treat. 2012. PMID: 22286314 Clinical Trial.
294 results